SCHEMBL3041685

SCHEMBL3041685

CCOC(=O)[C@@H]1CC(O)CN1C(=O)OC(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C19 P33261 1/20 0.50
CHRM2 P08172 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
FKBP1A P62942 2/20 0.39
NR1H2 P55055 1/20 0.38
ALDH1A1 P00352 3/20 0.37
ATM Q13315 1/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
TSHR P16473 1/20 0.37
MAPT P10636 1/20 0.37
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
RIPK1 Q13546 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2704430 1.00 POLB (0.50) POLBCYP1A2CYP3A4CYP2C19CHRM2
SCHEMBL2682785 1.00 POLB (0.50) POLBCYP1A2CYP3A4CYP2C19CHRM2
SCHEMBL9635522 1.00 POLB (0.50) POLBCYP1A2CYP3A4CYP2C19CHRM2
SCHEMBL2572678 1.00 POLB (0.50) POLBCYP1A2CYP3A4CYP2C19CHRM2
SCHEMBL116396 1.00 POLB (0.50) POLBCYP1A2CYP3A4CYP2C19CHRM2
SCHEMBL2202494 1.00 POLB (0.50) POLBCYP1A2CYP3A4CYP2C19CHRM2
SCHEMBL7807921 0.89 POLB (0.47) POLBCYP1A2CYP3A4CYP2C19CHRM2
SCHEMBL19262949 0.89 CYP3A4 (0.46) POLBCYP1A2CYP3A4CYP2C19CHRM2
SCHEMBL7811172 0.89 CYP1A2 (0.40) POLBCYP1A2CYP3A4CYP2C19CHRM2
SCHEMBL117368 0.89 CYP1A2 (0.40) POLBCYP1A2CYP3A4CYP2C19CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023183616-A1 NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME SENDA BIOSCIENCES, INC. (US) 2023-09-28 WO disclosed
EP-2993167-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES Ajinomoto Co., Inc. (JP) 2016-03-09 EP disclosed
US-20160046592-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES AJINOMOTO CO., INC. (JP) 2016-02-18 US disclosed
US-7651997-B2 Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2010-01-26 US disclosed
US-20070129289-A1 Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them THE TRUSEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2007-06-07 US disclosed
EP-1276491-B9 TAMANDARIN AND DIDEMNIN ANALOGS AND METHODS OF MAKING AND USING THEM UNIV PENNSYLVANIA (US) 2007-02-28 EP disclosed
EP-1276491-B1 TAMANDARIN AND DIDEMNIN ANALOGS AND METHODS OF MAKING AND USING THEM UNIV PENNSYLVANIA (US) 2006-09-20 EP disclosed
US-7064105-B2 Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2006-06-20 US disclosed
EP-1276491-A4 TAMANDARIN AND DIDEMNIN ANALOGS AND METHODS OF MAKING AND USING THEM UNIV PENNSYLVANIA (US) 2004-08-25 EP disclosed
EP-1276491-A1 TAMANDARIN AND DIDEMNIN ANALOGS AND METHODS OF MAKING AND USING THEM THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2003-01-22 EP disclosed
US-6399629-B1 PYRROLIDINES AND PIPERIDINES FOR TREATING MICROBIAL INFECTIONS BY REDUCING EXPORT OF COADMINISTERED ANTIMICROBIAL AGENT OR COMPOUND SYNTHESIZED BY MICROBES FOR THEIR GROWTH; REDUCING IN VIVO AVAILABILITY MICROCIDE PHARMACEUTICALS, INC. 2002-06-04 US disclosed
WO-2001076616-A1 TAMANDARIN AND DIDEMNIN ANALOGS AND METHODS OF MAKING AND USING THEM THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129289-A1 Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them PRAP1, PTMA, DHPS POLB 2323/4885CYP1A2 4305/4885CYP3A4 4131/4885
US-20160046592-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES PPARG, GPR119, PPARA POLB 2155/4885CYP1A2 638/4885CYP3A4 981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.